Mark Sarnak, an expert from Tufts University, discusses the intricate relationship between chronic kidney disease (CKD) and cardiovascular risks. He highlights the rising incidence of CKD driven by obesity and diabetes, and the significance of efficient screening. Sarnak delves into the latest guidelines for managing cardiovascular risk in CKD patients, including the use of innovative treatments like SGLT2 inhibitors. He also touches on the complexities of prescribing antiplatelet medications and the future of personalized medicine in cardiovascular care.